S S ORGANICS

Hyderabad, India Founded: 1990 • Age: 36 yrs Listed
Finished products and APIs are manufactured for therapeutic categories.

About S S ORGANICS

S S ORGANICS is a publicly listed company based in Hyderabad (India) founded in 1990. Finished products and APIs are manufactured for therapeutic categories. The company has 98 employees. Its chief executive, as recorded, is V N Sunanda Reddy. Its Indian entity Oxygenta Pharmaceutical Limited reported revenue of β‚Ή113 Cr. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides. Similar companies include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals; 1 of its 3 listed similar companies has raised funding.

Company details

SS Organics was founded in 1990 in Hyderabad, India, within the pharmaceutical sector. Finished products and active pharmaceutical ingredients (APIs) are produced across categories such as antibiotics, analgesics, respiratory, cardiovascular, gastrointestinal, and antifungal treatments. Manufacturing facilities are certified under ISO 9001:2000 standards, supporting operations focused on these therapeutic areas.

  • Headquarters Hyderabad, India
  • Employees 98
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website ssorganics.co.in
  • Legal Name S.S. Organics Ltd.
  • Date of Incorporation 27 Nov, 1990
  • Jurisdiction Medak, Telangana, India
Key Metrics
  • Market Cap
    ₹181 Cr

    OXYGENTAPH · BSE

  • Share Price
    ₹50.49

    +3.10% today

  • Revenue
    ₹113 Cr

    FY 2025-26 · +3.4% YoY

  • EBITDA
    −₹15.32 Cr

    Margin -13.6%

  • Net Profit
    −₹17.56 Cr

    FY 2025-26 · -69.7% YoY

  • Employee Count
    98

Board of directors of Oxygenta Pharmaceutical Limited (S S ORGANICS)

Oxygenta Pharmaceutical Limited is the primary company behind S S ORGANICS. The board of Oxygenta Pharmaceutical Limited currently have 8 directors; the longest-serving is Vedavathi Gangavaram, appointed in 2025. 41 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Vedavathi Gangavaram
DIN 02870966
Director20 Jun 20251 yr 4 moOxygenta Pharmaceutical Limited
Veera Reddy Arava
DIN 10832178
Director20 Jun 20251 yr 4 moOxygenta Pharmaceutical Limited
Sidda Reddy Kanuparthi
DIN 07156289
Director20 Jun 20251 yr 4 moOxygenta Pharmaceutical Limited
Sharvari Swapnil Shinde
DIN 11149764
Director20 Jun 20251 yr 4 moOxygenta Pharmaceutical Limited
Chandra Mouliswar Reddy Gangavaram
DIN 00046845
Whole-time director20 Jun 20251 yr 4 moOxygenta Pharmaceutical Limited
Balasubba Reddy Mamilla
DIN 01998852
Whole-time director20 Jun 20251 yr 4 moOxygenta Pharmaceutical Limited
Janardhana Reddy Yeddula
DIN 03207357
Additional Director23 May 20265 moOxygenta Pharmaceutical Limited
Amireddy Venkatesu Reddy
DIN 11087687
Additional Director23 May 20265 moOxygenta Pharmaceutical Limited

People of S S ORGANICS

1 people are tracked at S S ORGANICS (1 in leadership); the tracked headcount is 98.

NameRoleGroup
V N Sunanda Reddy
CEO & MDLeadership
Premium access

Complete people profiles for S S ORGANICS

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of S S ORGANICS

S S ORGANICS is a publicly listed company on the BSE with ticker symbol OXYGENTAPH in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date23 Jul 2021
  • Listed onBSE: 524636
  • Listed entityOxygenta Pharmaceutical Limited
  • Exchange sectorPharmaceuticals

Financials of S S ORGANICS

Exchange-reported figures of Oxygenta Pharmaceutical Limited, the listed company behind S S ORGANICS (BSE: OXYGENTAPH).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹113 Cr
+3.4% YoY
EBITDA
−₹15.32 Cr
-56.0% YoY
Profit After Tax
−₹17.56 Cr
-69.7% YoY
Net Worth
−₹42.69 Cr
-66.5% YoY
Total Assets
₹67.86 Cr
+80.1% YoY
Total Debt
₹110 Cr
+76.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue11310939.6430.9960.5252.0313.72
Revenue growth+3.4%+175.7%+27.9%-48.8%+16.3%+279.2%-
EBITDA(15.32)(9.82)(9.71)(7.97)0.673.85(7.86)
EBITDA margin-13.6%-9.0%-24.5%-25.7%+1.1%+7.4%-57.3%
Profit before tax(22.17)(14.35)(13.86)(11.37)(0.48)3.15(5.93)
Net profit(17.56)(10.35)(3.51)(10.85)(1.03)0.90(9.77)
Net profit margin-15.5%-9.5%-8.9%-35.0%-1.7%+1.7%-71.2%
EPS (β‚Ή)(4.75)(2.78)(1.04)(8.15)(0.43)2.87(5.67)
Balance sheet
Total assets67.8637.6737.7325.4522.7317.883.12
Net worth(42.69)(25.64)(20.13)(46.20)(34.63)(38.02)(40.95)
Total debt11062.2357.2368.0052.1347.8926.92
Cash & bank2.150.120.100.110.160.450.12
Net working capital(0.40)(14.20)(1.35)(2.13)2.581.29(8.72)
Cash flow
Cash from operations(27.75)2.83(13.05)(1.63)(1.68)(1.62)(2.59)
Cash from investing(14.39)(11.32)(4.09)(9.64)(4.94)(6.72)(0.50)
Cash from financing42.568.4917.1311.226.338.673.19
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue33.4937.0049.6133.9314.3015.1349.4733.21
Revenue growth (YoY)+134.2%+144.6%+0.3%+2.2%+2.1%+19.9%--
Other income0.020.020.170.00(0.06)0.170.050.49
Total expenses33.4736.4549.5038.0118.8821.9851.4237.56
EBITDA0.020.550.11(4.08)(4.58)(6.85)(1.95)(4.35)
EBITDA margin+0.1%+1.5%+0.2%-12.0%-32.0%-45.3%-3.9%-13.1%
Depreciation0.710.62(0.24)0.860.860.85(0.23)0.71
Interest2.732.461.811.390.950.632.130.39
Profit before tax(3.40)(2.51)(1.29)(6.33)(6.45)(8.16)(3.80)(4.96)
Tax(0.66)(0.40)0.42(1.48)(1.51)(2.04)(1.65)(1.03)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 17 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue33.4937.0049.6133.9314.3015.1349.4733.21
Revenue growth (YoY)+134.2%+144.6%+0.3%+2.2%+2.1%+19.9%--
Other income0.020.020.170.00(0.06)0.170.050.49
Total expenses33.4736.4549.5038.0118.8821.9851.4237.56
EBITDA0.020.550.11(4.08)(4.58)(6.85)(1.95)(4.35)
EBITDA margin+0.1%+1.5%+0.2%-12.0%-32.0%-45.3%-3.9%-13.1%
Depreciation0.710.62(0.24)0.860.860.85(0.23)0.71
Interest2.732.461.811.390.950.632.130.39
Profit before tax(3.40)(2.51)(1.29)(6.33)(6.45)(8.16)(3.80)(4.96)
Tax(0.66)(0.40)0.42(1.48)(1.51)(2.04)(1.65)(1.03)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue11310939.6430.9960.5252.0313.72
Revenue growth+3.4%+175.7%+27.9%-48.8%+16.3%+279.2%-
Other income0.291.310.100.141.362.284.02
Total expenses12811949.3538.9659.8548.1821.58
Employee cost7.616.765.965.740.584.082.50
EBITDA(15.32)(9.82)(9.71)(7.97)0.673.85(7.86)
EBITDA margin-13.6%-9.0%-24.5%-25.7%+1.1%+7.4%-57.3%
Depreciation2.323.612.662.051.591.201.00
Interest4.822.231.591.490.921.781.09
Profit before tax(22.17)(14.35)(13.86)(11.37)(0.48)3.15(5.93)
Tax(4.61)(4.05)(10.39)0.200.120.21(0.15)
Net profit(17.56)(10.35)(3.51)(10.85)(1.03)0.90(9.77)
Net profit margin-15.5%-9.5%-8.9%-35.0%-1.7%+1.7%-71.2%
EPS (β‚Ή)(4.75)(2.78)(1.04)(8.15)(0.43)2.87(5.67)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital36.9836.9833.4814.2014.2010.2010.20
Reserves & surplus(79.67)(62.62)(54.17)(60.40)(48.83)(48.22)(51.15)
Shareholders' funds (net worth)(42.69)(25.64)(20.13)(46.20)(34.63)(38.02)(40.95)
Secured loans43.1113.9210.8641.9933.862.850.50
Unsecured loans66.4548.3146.3726.0118.2745.0426.42
Total debt11062.2357.2368.0052.1347.8926.92
Total liabilities67.8637.6737.7325.4522.7317.883.12
Assets
Gross block74.5861.4950.5346.4336.4431.1825.10
Net block47.6036.8329.3527.9119.9816.3111.42
Capital work in progress0.000.230.000.000.340.650.00
Investments0.470.050.050.050.050.050.05
Inventories29.4220.5113.7211.717.2812.114.25
Sundry debtors10.035.107.3610.161.581.610.42
Cash & bank balances2.150.120.100.110.160.450.12
Loans & advances9.835.212.933.040.551.771.98
Total current assets51.4330.9424.1125.029.5715.946.77
Total current liabilities51.8345.1425.4627.156.9914.6515.49
Net working capital(0.40)(14.20)(1.35)(2.13)2.581.29(8.72)
Total assets67.8637.6737.7325.4522.7317.883.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.000.000.110.160.450.120.02
Net cash from operating activities(27.75)2.83(13.05)(1.63)(1.68)(1.62)(2.59)
Net cash from investing activities(14.39)(11.32)(4.09)(9.64)(4.94)(6.72)(0.50)
Net cash from financing activities42.568.4917.1311.226.338.673.19
Net change in cash0.420.00(0.01)(0.05)(0.29)0.330.10
Closing cash2.150.120.100.110.160.450.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3.4%+175.7%+27.9%-48.8%+16.3%+279.2%-
EBITDA growth-56.0%-1.1%-21.8%-1289.6%-82.6%+149.0%-
PBT growth-54.5%-3.5%-21.9%-2268.8%-+9998.0%-69.4%
Net income growth-69.7%-194.9%+67.7%-953.4%-214.4%+109.2%-
Revenue CAGR (3Y)+53.9%+21.8%-8.7%+31.2%+43.4%+59.3%+19.0%
EBITDA CAGR (3Y)+24.3%--+0.5%--+17.5%
Profitability & leverage
Net income margin-15.5%-9.4%-8.8%-37.3%-1.0%+5.7%-42.1%
Return on capital employed0.0%0.0%0.0%0.0%0.0%+7.9%0.0%
Return on net worth0.0%0.0%0.0%0.0%0.0%-5.8%0.0%
Debt / equity0.000.000.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover-27.32-16.60-12.85-14.87-100.0067.17-12.30
Efficiency & per share
Fixed asset turnover1.661.950.820.751.791.850.55
Inventory turnover4.536.393.123.266.246.362.86
Debtors turnover14.9317.544.535.2837.9451.2629.51
EPS (β‚Ή)(4.75)(2.78)(1.04)(8.15)(0.43)2.87(5.67)
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)(11.54)(6.93)(6.18)(32.53)(24.38)(37.27)(40.14)

Similar companies to S S ORGANICS

S S ORGANICS has 3 listed similar companies in our database, 1 of them funded. They include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
indoco.com1947Mumbai, India6,291
APIs manufacturing and formulation services are provided in therapeutic segments.
concordbiotech.com2000Ahmedabad, India1,598
APIs and enzymes are manufactured through fermentation by the CDMO.
bdrpharma.com2003Mumbai, India$88.16M1,864
APIs and finished products are developed and manufactured.
Premium access

Detailed similar companies of S S ORGANICS

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as S S ORGANICS (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about S S Organics

Premium access

Complete news archive for S S ORGANICS

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about S S ORGANICS

S S ORGANICS was founded in 1990.

S S ORGANICS is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

V N Sunanda Reddy is the CEO of S S ORGANICS, as recorded in our data.

S S ORGANICS has 98 employees.

The primary company behind S S ORGANICS, Oxygenta Pharmaceutical Limited, reported revenue of β‚Ή113 Cr for FY 2026, up 3% year on year.

SS Organics was founded in 1990 in Hyderabad, India, within the pharmaceutical sector. Finished products and active pharmaceutical ingredients (APIs) are produced across categories such as antibiotics, analgesics, respiratory, cardiovascular, gastrointestinal, and antifungal treatments. Manufacturing facilities are certified under ISO 9001:2000 standards, supporting operations focused on these therapeutic areas.

S S ORGANICS's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Indoco Remedies.

Yes, S S ORGANICS is publicly traded on BSE under the ticker symbol OXYGENTAPH.

S S ORGANICS operates through Oxygenta Pharmaceutical Limited.

The legal entities of S S ORGANICS currently have 10 directors, including Vedavathi Gangavaram, Veera Reddy Arava, Sidda Reddy Kanuparthi and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available